Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Daiichi Sankyo
Daiichi Sankyo
Activities:
Packaging
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
Broughton receives flexible scope ISO 17025 accreditation
New certification allows accreditation without prior approval
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Therapeutic: datopotamab deruxtecan for breast cancer
Of all the various forms of breast cancer, triple negative is the most aggressive subtype
Research & Development
AstraZeneca and Daiichi Sankyo reveal phase 3 lung cancer study
Results for the TROP2-directed antibody drug conjugate demonstrated statistically significant improvement in progression-free survival vs. standard chemotherapy
Drug Delivery
ProLynx collaborates with Daiichi Sankyo on drug delivery
The collaboration will evaluate the utility of the releasable linker technology in half-life extension of small-molecule drugs after intravitreal injection
Finance
Heptares Therapeutics enters agreement with Daichi Sankyo
The collaboration aims to discover and develop novel, small-molecules for the treatment of pain
Pharmaceutical
Amgen and Daiichi Sankyo to commercialise biosimilars in Japan
The exclusive agreement includes nine biosimilars in late-stage development
Drug Delivery
Nitto Denko enters drug delivery partnership with Daiichi Sankyo
To accelerate the commercialisation of Nitto’s PassPort transdermal drug delivery technology
Research & Development
Daiichi Sankyo appoints Antoine Yver as Global Head, Oncology Research and Development
He will lead all global R&D across the oncology therapeutic area
Subscribe now